^
Association details:
| Biomarker: | HER-2 L755S |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2- positive breast cancer cell models
Published date:
11/17/2020
Excerpt:
RNA-seq analysis revealed the presence of HER2 L755S mutation in the LapR and NrbR derivatives, but not in P cells...HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2- positive breast cancer cell models...On the other hand, the resistant derivatives were cross-resistant to Tuca, both as a single-agent and in combination with T.
